Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
After a follow-up of 24 months, the two-year relapse free survival was 54% and the two-year overall survival rate was 60%.
The effect of elevated BMI was more pronounced in older adolescent and young adults (AYAs) compared to younger AYAs.
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
The strategy is “potentially translatable to all T-cell derived hematological malignancies," according to researchers.
Elias Jabbour, MD, discusses the most burning questions in acute lymphoblastic leukemia (ALL).
The pooled ORR was 97% and the pooled complete remission rate was 93% in patients with ALL.
Advertisement
The study included 255 patients aged one to 30 years with low-risk first-relapse B-ALL.
Researchers conducted the study because the "optimal treatment strategy for these patients is still a matter of debate.”
JZP458, which is approved in the United States and Canada, is a new Erwinia-derived asparaginase.
Researchers retrospectively analyzed treatment outcomes of 69 patients with relapsed or refractory CRLF2-rearranged B-ALL.
Low hypodiploidy “defines a rare subtype” of B-cell ALL with a “dismal outcome.”
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
The award is the society’s “most prestigious award" and “serves to honor those that have been pioneers in their work."
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
Investigators studied mechanisms of resistance to BH3 mimetics to “develop rational combination strategies" for T-cell ALL.
The researchers reported that 46.7% of patients had a BMI in the overweight or obese range.
Induction chemotherapy failure occurred in 10.3% of cases and was significantly associated with increasing age.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.